Viking Therapeutics Obesity Injection Cuts Weight and Sustains Loss at Lower Dose, Stock Jumps

The notable signal here is not the weight loss itself but the durability of effect after reducing dosing frequency, which speaks to tolerability and patient adherence — the practical bottleneck for any chronic obesity therapy. For Viking, this matters because earlier trial setbacks had raised questions about its competitive position in a crowded field. The open question is whether this small exploratory cohort's result holds up in larger, controlled studies, and whether reduced-frequency dosing becomes a genuine differentiator or remains an early-stage curiosity.